Broncus Holding Corporation (HKG:2216)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
1.190
+0.030 (2.59%)
Apr 29, 2026, 4:08 PM HKT
-51.03%
Market Cap 627.22M
Revenue (ttm) 1.35M
Net Income (ttm) -139.13M
Shares Out 527.08M
EPS (ttm) -0.29
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 362,000
Average Volume 1,058,700
Open 1.160
Previous Close 1.160
Day's Range 1.150 - 1.210
52-Week Range 1.000 - 3.720
Beta 1.25
RSI 40.64
Earnings Date Mar 31, 2026

About Broncus Holding

Broncus Holding Corporation, a medical device company, focuses on the development of interventional pulmonology products in Mainland China, the European Union, and internationally. The company offers InterVapor, a thermal vapor treatment system to treat chronic obstructive pulmonary disease (COPD); BroncAblate Radiofrequency Ablation System, a transbronchial interventional treatment product for lung cancer; Targeted Lung Denervation (TLD) Radiofrequency Ablation System for the treatment of COPD; H-Marker, a pulmonary surgical marker can be used... [Read more]

Industry Medical Devices
Sector Healthcare
Founded 2012
Employees 171
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2216
Full Company Profile

Financial Performance

In 2025, Broncus Holding's revenue was $174,000, a decrease of -97.86% compared to the previous year's $8.13 million. Losses were -$17.88 million, 16.8% more than in 2024.

Financial numbers in USD Financial Statements

News

There is no news available yet.